Accelerated weight loss with feeling full and appetite control. Ask us Today.
Semaglutide is a Glucagon-like peptide-1 (GLP-1) produced by the gut. It increases insulin production, a hormone that lowers the blood sugar level while inhibiting glucagon secretion, which is a hormone that raises blood sugar, reduces appetite and energy intake while delaying gastric emptying.
It was first developed in 2012 by Novo Nordisk as a longer-acting option to Liraglutide. In 2017 this drug was approved as an anti-diabetic medication used to treat type 2 diabetes and obesity.